Back to User profile » Dr Michael Pollack
Papers published by Dr Michael Pollack:
Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study
Calle Rubio M, Trigueros Carrero JA, Chaparro Briones P, Escudero Herrera L, Pollack M, Hernández Subirá I, Sánchez-Covisa J
International Journal of Chronic Obstructive Pulmonary Disease 2025, 20:999-1008
Published Date: 9 April 2025
Patterns of Rescue and Maintenance Medication Claims Surrounding an Asthma Exacerbation in Patients Treated as Intermittent or Mild Persistent Asthma
Lanz MJ, Pollack M, Gilbert IA, Gandhi HN, Tkacz JP, Lugogo NL
Journal of Asthma and Allergy 2024, 17:871-877
Published Date: 14 September 2024
Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:1799-1800
Published Date: 6 August 2024
Disease Burden and Health-Related Quality of Life (HRQoL) of Chronic Obstructive Pulmonary Disease (COPD) in the US – Evidence from the Medical Expenditure Panel Survey (MEPS) from 2016-2019
Roberts MH, Mannino DM, Mapel DW, Lunacsek O, Amin S, Farrelly E, Feigler N, Pollack MF
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:1033-1046
Published Date: 13 May 2024
Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study
Daniels K, Lanes S, Tave A, Pollack MF, Mannino DM, Criner G, Neikirk A, Rhodes K, Feigler N, Nordon C
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:225-241
Published Date: 18 January 2024
Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2245-2256
Published Date: 12 October 2023
Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
Lugogo N, Gilbert I, Pollack M, Gandhi H, Tkacz J, Lanz MJ
Journal of Asthma and Allergy 2023, 16:579-584
Published Date: 31 May 2023
A 4-Year Retrospective Claims Analysis of Oral Corticosteroid Use and Health Conditions in Newly Diagnosed Medicare FFS Patients with COPD
Bazell C, Pollack M, Comellas AP, Sethi S, Alston M, Pyenson B, Hansen D, Caplen M, Staresinic A, Styczynski J, Feigler N
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2635-2652
Published Date: 17 October 2022
Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population
Sethi S, Make BJ, Robinson SB, Kumar S, Pollack M, Moretz C, Dreyfus J, Xi A, Powell D, Feigler N
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:593-608
Published Date: 20 March 2022
CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
Alves L, Pullen R, Hurst JR, Miravitlles M, Carter V, Chen R, Couper A, Dransfield M, Evans A, Hardjojo A, Jones D, Jones R, Kerr M, Kostikas K, Marshall J, Martinez F, Melle MV, Murray R, Muro S, Nordon C, Pollack M, Price C, Sharma A, Singh D, Winders T, Price DB
Patient Related Outcome Measures 2022, 13:53-68
Published Date: 23 February 2022
PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation
Tkacz J, Evans KA, Touchette DR, Portillo E, Strange C, Staresinic A, Feigler N, Patel S, Pollack M
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:329-342
Published Date: 10 February 2022